Honor

Exploring The Best Solutions For The Future Health Of Humanity

Shaanxi Weishino Biotechnology Co., Ltd. was established in December 2021, located in the Science and Technology Enterprise Accelerator Park of Xi'an High tech Zone, Shaanxi Province. At present, we have more than 10 full-time and part-time R&D personnel, and have hired 6 R&D consultants from well-known universities in China. The company's main business covers DNA nanomaterials, molecular biological reagents and culture media, gel dressings, biosynthetic materials, and provides customized services for various products.

The company currently has a molecular biology laboratory, a professional testing room, a 10000 level ultra clean room, and approximately 1000 square meters. We currently have advanced scientific research equipment including fluorescence quantitative PCR enzyme-linked immunosorbent assay (ELISA) reader, chemiluminescence system, ultra micro ultraviolet spectrophotometer, biosafety cabinet, ultra clean bench, cell counter, fluorescence inverted microscope, flow cytometer, nanoparticle potential analyzer, etc.

The company adheres to the core values of "caring for the world and benefiting the public", adheres to the business philosophy of talent as the guide and technology as the foundation, and is committed to research and development investment in fields such as nanotechnology, genetic engineering, molecular biology, and biotechnology. We hope to make greater contributions to human health and the development of biotechnology with high-quality products and services.

Exploring The Best Solutions For The Future Health Of Humanity

Honor

Honor

Process

Development

2021

2021: Foundation laying and sailing

Laying the foundation and setting sail

December 2021: Shaanxi Weishino Biotechnology Co., Ltd. was officially registered and established at the Xi'an Caotang National Science and Technology Enterprise Accelerator. It is an innovative research and development enterprise specializing in medical testing, diagnosis, and treatment. The company adheres to the core values of "caring for the world and benefiting the public", adheres to the business philosophy of talent as the guide and technology as the foundation, and strives to be a pioneer in the field of disease early screening, with the mission of "exploring the best solutions for the future health of humanity".


2024

2022-2024: Rapid Growth

The company successfully developed M13mp18 DNA single strand series products, gel products, competent products and biosynthetic products, enriched the company's product categories, expanded the market, quickly opened the market with innovative design and high cost performance, and won the first batch of customer recognition. We have applied for and authorized over 10 national invention patents and utility model patents, ensuring that the company has mastered core technologies. The team continues to grow, from 4 people in the initial stage to 15 people, attracting many top talents in the industry to join.
2025

2025 present: Smart Creation for the Future

Fully utilize AI and big data technologies to optimize research and development, production, and service processes, and enhance customer satisfaction. Jointly build technology alliances with domestic and foreign peers to promote industry standardization and sustainable development. In the future, the company will continue to anchor the goal of being a pioneer in the field of early disease screening, invest continuously, and create greater value for users.
2025

milestone

Accumulated customer service: 10000+

Number of patents: 15

Product category: 12

Culture

Corporate Culture

Corporate Vision

Corporate Vision

To become an innovator and guardian in the field of global disease early screening, using cutting-edge technology and innovative solutions to enable every life to enjoy earlier health foresight and help build a disease free future world.

Corporate Vision